



# Lumizyme® (alglucosidase alfa)

(Intravenous)

Document Number: MODA-0079

## Last Review Date: 04/07/2025 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 02/2013, 02/2014, 08/2014, 07/2015, 10/2016, 10/2017, 10/2018, 02/2019, 02/2020, 02/2021, 09/2021, 02/2022, 02/2023, 02/2024, 04/2025

#### I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

## II. Dosing Limits

#### Max Units (per dose and over time) [HCPCS Unit]:

• 230 billable units every 14 days

## III. Initial Approval Criteria<sup>1,4</sup>

Site of care specialty infusion program requirements are met (refer to Moda Site of Care Policy).

Coverage is provided in the following conditions:

- Documented baseline age-appropriate values for one or more of the following:
  - Infantile-onset disease: muscle weakness, motor function, respiratory function, cardiac involvement, percent predicted forced vital capacity (FVC), and/or 6-minute walk test (6-MWT); OR
  - o Late-onset (non-infantile) disease: FVC and/or 6-MWT; AND

\*\***NOTE:** For very young patients in which FVC or 6-MWT are not suitable for measuring, requests will be reviewed on a case-by case basis.

#### Universal Criteria<sup>1</sup>

- Will not be used in combination with other enzyme replacement therapies; AND
- Patients susceptible to fluid volume overload or those with an acute underlying respiratory illness or compromised cardiac or respiratory function will be closely monitored for exacerbation of their cardiac or respiratory status during infusion; **AND**

#### Pompe Disease (Acid Alpha-Glucosidase (GAA) deficiency) † Φ<sup>1,4</sup>

- Diagnosis has been confirmed by one of the following:
  - Deficiency of acid alpha-glucosidase (GAA) enzyme activity\*\*; OR
  - Detection of biallelic pathogenic variants in the GAA gene by molecular genetic testing

**\*\*NOTE:** The diagnosis of Infantile-Onset Pompe Disease (IOPD) can be established rapidly after a positive newborn screening (NBS) result when physical examination, echocardiography, and elevated CPK support the diagnosis. It is recommended that the diagnosis be confirmed either by molecular genetic testing or by measurement of GAA activity in another tissue.<sup>4</sup>

**†** FDA Approved Indication(s); **‡** Compendia Recommended Indication(s); **Φ** Orphan Drug

## IV. Renewal Criteria <sup>1,4</sup>

Coverage may be renewed based on the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hypersensitivity reactions including anaphylaxis, infusion-associated reactions (e.g., pyrexia, chills, flu-like illness, rash/urticaria, pruritus, etc.), immune-mediated reactions, acute cardiorespiratory failure, cardiac arrhythmia during general anesthesia, etc.; **AND**
- Patient is being monitored for antibody formation (including neutralizing antibodies); AND
- Patient has demonstrated a beneficial response to therapy compared to pretreatment ageappropriate baseline values in one or more of the following:
  - Infantile-onset disease: stabilization or improvement in muscle weakness, motor function, respiratory function, cardiac involvement, FVC and/or 6-MWT; OR
  - o Late-onset (non-infantile) disease: stabilization or improvement in FVC and/or 6-MWT

## V. Dosage/Administration<sup>1</sup>

Indication	Dose
	Administer 20 mg/kg body weight as an intravenous (IV) infusion every 2 weeks

## VI. Billing Code/Availability Information

#### HCPCS Code:

• J0221 – Injection, alglucosidase alfa, (lumizyme), 10 mg; 1 billable unit = 10 mg

#### NDC:


• Lumizyme 50 mg single-dose vial for injection: 58468-0160-xx

#### VII. References

1. Lumizyme [package insert]. Cambridge, MA; Genzyme Corporation; December 2024. Accessed March 2025.

Page 2







- Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012 Mar; 45(3):319-33. doi: 10.1002/mus.22329. Epub 2011 Dec 15.
- 3. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guidelines. *Genet Med* 2006; 8:267-88.
- 4. Leslie N, Bailey L. Pompe Disease. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1261/. Initial Posting: August 31, 2007; Last Update: November 2, 2023. Accessed on March 12, 2025.
- Tarnopolsky M, Katzberg H, Petrof BJ, et al. Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel. Can J Neurol Sci. 2016 Jul;43(4):472-85.
- 6. Kishnani PS, Hwu WL, et al. Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement. Pediatrics 2017 Jul:(1):S1-S3.
- van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15;362(15):1396-406. doi: 10.1056/NEJMoa0909859.
- Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009 Mar;11(3):210-9. doi: 10.1097/GIM.0b013e31819d0996.
- 9. Sawada T, Kido J, Nakamura K. Newborn Screening for Pompe Disease. Int J Neonatal Screen. 2020 Jun; 6(2): 31.Published online 2020 Apr 5. doi: 10.3390/ijns6020031

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E74.02	Pompe disease

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)


Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <a href="https://www.cms.gov/medicare-coverage-database/search.aspx">https://www.cms.gov/medicare-coverage-database/search.aspx</a>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Administrative Contractor (MAC) Jurisdictions				
Jurisdiction	Applicable State/US Territory	Contractor		
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC		

Page 3

**Medical Necessity Criteria** 



Medicare Part B Administrative Contractor (MAC) Jurisdictions				
Jurisdiction	Applicable State/US Territory	Contractor		
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC		
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)		
6	MN, WI, IL	National Government Services, Inc. (NGS)		
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.		
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)		
N (9)	FL, PR, VI	First Coast Service Options, Inc.		
J (10)	TN, GA, AL	Palmetto GBA		
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA		
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.		
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)		
15	КҮ, ОН	CGS Administrators, LLC		

Medical Necessity Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.